Purple Biotech (PPBT) Shares Outstanding (Weighted Average) (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Shares Outstanding (Weighted Average) data on file, last reported at $153.7 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $153.7 million, up 3.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $153.7 million (up 3.9% YoY), and the FY2025 annual result was $960.1 million, up 550.34% from the prior year.
• Shares Outstanding (Weighted Average) rose to $153.7 million in Q1 2026 per PPBT's latest filing, from $152.5 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $153.7 million in Q1 2026 and troughed at $904054.0 in Q4 2022.
• A 5-year average of $130.7 million and a median of $133.7 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Weighted Average) slumped 94.85% in 2022, then soared 14631.86% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $904054.0 in 2022, then soared by 14631.86% to $133.2 million in 2023, then increased by 10.85% to $147.6 million in 2024, then increased by 3.29% to $152.5 million in 2025, then advanced by 0.8% to $153.7 million in 2026.
• Business Quant data shows PPBT's Shares Outstanding (Weighted Average) at $153.7 million in Q1 2026, $152.5 million in Q4 2025, and $151.8 million in Q3 2025.